12:00 AM
 | 
Mar 20, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Enbrel etanercept: Phase I data; Phase II/III; marketed to treat rheumatoid arthritis

IMNX presented 6-month follow-up data from 12 patients in a 47-patient Phase I study showing that Enbrel was well-tolerated, with no increase in frequency of adverse events (see BioCentury, March 15, 1999). The 12...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >